Chinese TCM distribution and pharmaceutical company that became notorious for a major accounting-fraud scandal in 2019.
Chinese TCM distribution and pharmaceutical company that became notorious for a major accounting-fraud scandal in 2019.
Moat: none. Diminished brand trust after a landmark accounting-fraud case damaged investor and business confidence.
Headquarters: Guangdong, China · Employees: 5,492
Size Kangmei Pharmaceutical (600518.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $2.61B, the 910th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥1.28 on 18 Nov 2026.
Performance Over six months the shares fell 21.0%, against -8.4% for the median peer and -20.0% for the China market (cap-weighted) — 6th lowest of 21 in its peer set.
Growth Revenue fell 5.6% over the last twelve months (peer median +5.1%); the operating margin is -6.7% (peer median 11.3%).
Valuation It trades at 3.3× enterprise value to sales against a peer median of 9.0× (7th cheapest of 20).
Capital Return on invested capital runs 9.0 points below its cost of capital (5.1% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥4.97B | CN¥5.24B | CN¥5.12B | CN¥5.15B | CN¥4.17B |
| Revenue growth | — | +2% | -1% | +23% | — |
| Gross profit | CN¥850M | CN¥840M | CN¥465M | CN¥874M | CN¥372M |
| EBITDA | -CN¥3.03M | CN¥159M | -CN¥52.6M | CN¥475M | -CN¥661M |
| Net income | CN¥29.5M | CN¥10.3M | CN¥8.57M | CN¥103M | -CN¥2.69B |
| Free cash flow | CN¥11.8M | -CN¥106M | -CN¥489M | -CN¥417M | -CN¥798M |
| Capital expenditure | CN¥218M | CN¥217M | CN¥61.7M | CN¥99.7M | CN¥48.1M |
| Total debt | CN¥322M | CN¥309M | CN¥213M | CN¥306M | CN¥1.15B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Kangmei Pharmaceutical 600518.SS | $2.61B | -21% | -6% | -7% | 3.3× | n/a |
| Beijing TongRenTang 600085.SS | $4.91B | -12% | -17% | 8% | 2.2× | 1.7% |
| Yunnan Baiyao 000538.SZ | $15.0B | +11% | +5% | 11% | 2.1× | -0.2% |
| China Resources Sanjiu Medical & Pharmaceutical 000999.SZ | $6.59B | +6% | +4% | 14% | 1.9× | -6.2% |
| Jointown Pharmaceutical 600998.SS | $3.99B | +7% | +9% | 2% | 0.4× | 0.2% |
| Sinopharm 1099.HK | $6.74B | 0% | +3% | 3% | 0.3× | -7.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 600518.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -0.8% | -6.7% | 10th highest of 21 |
| 6-month return | -21.0% | -8.4% | 6th lowest of 21 |
| Distance from 52-week high | -40.7% | -33.4% | 8th lowest of 21 |
| Revenue growth (TTM) | -5.6% | +5.1% | 8th lowest of 20 |
| Operating margin | -6.7% | 11.3% | 5th lowest of 20 |
| EV / Sales | 3.3× | 9.0× | 7th cheapest of 20 |
| ROIC minus cost of capital | -9.0 pp | -1.2 pp | 3rd lowest of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Kangmei Pharmaceutical 600518.SS | China | $2.61B | -21% | -6% | -7% | 3.3× | n/a | n/a |
| IDEAYA Biosciences IDYA | United States | $2.56B | -11% | -83% | -1,267% | 48.0× | n/a | n/a |
| BioArctic BIOA-B.ST | Sweden | $2.66B | -9% | -46% | 22% | 25.1× | 25.5% | +100.1% |
| Hybio Pharmaceutical 300199.SZ | China | $2.68B | -8% | +70% | 31% | 12.9× | 37.4% | +6.1% |
| Betta Pharmaceuticals 300558.SZ | China | $2.70B | -15% | +16% | 11% | 5.2× | 23.2% | +14.0% |
| Yili Chuanning Biotechnology 301301.SZ | China | $2.49B | -24% | -14% | 16% | 4.2× | 3.4% | +4.8% |
| Almirall ALM.MC | Spain | $2.46B | -13% | +24% | 8% | 1.9× | 6.1% | +6.5% |
| Prestige Consumer Healthcare PBH | United States | $2.40B | +7% | +5% | 25% | 3.8× | 2.3% | +2.9% |
| InSilico Medicine Cayman TopCo 3696.HK | Hong Kong | $2.40B | -33% | +153% | -7% | 13.6× | 37.9% | +22.9% |
| Keymed Biosciences 2162.HK | Hong Kong | $2.39B | +7% | 0% | -73% | 16.8× | n/a | n/a |
| Joincare Pharmaceutical Group Industry 600380.SS | China | $2.85B | 0% | -12% | 18% | 1.6× | -13.1% | +2.4% |
| HUTCHMED (China) 0013.HK | Hong Kong | $2.38B | +14% | -9% | -6% | 2.0× | 47.0% | +19.3% |
| NewAmsterdam Pharma NAMS | United States | $2.37B | -45% | -26% | -900% | 67.0× | n/a | n/a |
| Sam Chun Dang Pharm 000250.KS | South Korea | $2.36B | -66% | +23% | 7% | 11.8× | n/a | n/a |
| Perrigo PRGO | United States | $2.35B | +52% | -4% | 5% | 1.3× | 14.1% | +0.8% |
| Regencell Bioscience RGC | United States | $2.33B | -83% | n/a | n/a | n/a | n/a | n/a |
| Acrobiosystems 301080.SZ | China | $2.31B | +65% | +29% | 17% | 14.0× | 41.3% | +27.7% |
| Neuland Laboratories NEULANDLAB.NS | India | $2.95B | +28% | +50% | 26% | 11.9× | n/a | n/a |
| China Medical System 0867.HK | Hong Kong | $2.95B | -15% | +15% | 20% | 1.8× | 1.1% | +2.7% |
| Chengdu Kanghong Pharmaceutical 002773.SZ | China | $2.99B | -1% | -11% | 24% | 3.3× | -3.3% | +7.0% |
| Vericel VCEL | United States | $2.99B | +66% | +25% | 8% | 9.0× | 46.5% | +17.3% |